Merck & Co Inc (MRK)

neg -1.43
Today's Range: 49.32 - 51.39 | MRK Avg Daily Volume: 11,921,200
Last Update: 10/06/15 - 4:00 PM EDT
Volume: 16,441,559
YTD Performance: -9.79%
Open: $51.09
Previous Close: $51.23
52 Week Range: $45.69 - $63.62
Oustanding Shares: 2,816,635,020
Market Cap: 141,226,079,903
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 6 6
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.08 2.08
Latest Dividend: 0.45
Latest Dividend Yield: 3.59%
Dividend Ex-Date: 09/11/15
Price Earnings Ratio: 14.79
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
14.79 14.80 24.59
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-11.17% -14.47% 10.70%
Revenue -4.10 -0.12 -0.04
Net Income 164.20 0.87 0.23
EPS 176.90 1.02 0.26
Earnings for MRK:
Revenue 42.24B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.91 $0.91 $3.50 $3.81
Number of Analysts 9 7 11 12
High Estimate $0.96 $0.92 $3.55 $4.01
Low Estimate $0.87 $0.89 $3.45 $3.68
Prior Year $0.90 $0.87 $3.49 $3.50
Growth Rate (Year over Year) 1.48% 4.11% 0.42% 8.72%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Some smaller biotechs offer good value at current levels.
High-yielding stocks no longer offer protection.
Sep 21, 2015 | 7:18 AM EDT
Shares of MRK now seen reaching $66, according to BMO Capital. Estimates also cut, as Januvia could faced increased competition. Outper...
Investors have been distracted by the Fed, and that's a shame.
This 15-stock basket offers a stable and growing income stream along with appreciation potential.
Currencies and other headwinds come into play.

Lilly Up Nicely, Merck Down Real Money Pro($)

Eli Lilly (LLY) is up 5% following positive top-line Jardiance results for diabetes. Meanwhile, Merck (MRK) is down 4% on competitive concerns.
Aug 13, 2015 | 7:19 AM EDT
MRK was upgraded from Market Perform to Outperform, BMO Capital said. $70 price target. Pipeline should drive strong future growth.&nbs...

Novice Trade: MRK Real Money Pro($)

We have identified an opportunity in the October 60 calls for an upside play.

Columnist Conversations

Yum's getting ridiculous again because you have to wait for the call tomorrow and no one knows what will be sa...
My view is that the bulls have it wrong and that the preoccupation with the price momentum over the last two d...
Does the YUM miss call into question the optimism regarding the Chinese consumer?


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.